Humacyte (NASDAQ:HUMA - Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.07, Zacks reports. The business had revenue of $7.23 million during the quarter, compared to analyst estimates of $0.64 million.
Humacyte Stock Performance
Humacyte stock traded down $0.15 during trading on Tuesday, reaching $1.56. 6,029,444 shares of the company's stock were exchanged, compared to its average volume of 3,376,224. Humacyte has a 52-week low of $1.55 and a 52-week high of $9.97. The firm has a market cap of $195.71 million, a price-to-earnings ratio of -1.16 and a beta of 1.36. The company's 50-day moving average is $3.56 and its two-hundred day moving average is $4.47.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on HUMA shares. Benchmark restated a "buy" rating on shares of Humacyte in a report on Thursday, February 27th. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Humacyte in a research note on Wednesday, March 12th. Finally, D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of Humacyte in a report on Wednesday, March 26th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $13.71.
Check Out Our Latest Stock Analysis on HUMA
Humacyte Company Profile
(
Get Free Report)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Read More
Before you consider Humacyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humacyte wasn't on the list.
While Humacyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
